| Tuesday 15 May |
| Amerisur Resources |
| Macfarlane Group |
| Spirax-Sarco Engineering |
| Anglo Pacific Group |
| Charles Taylor |
| Vitec Group |
| IWG |
| UBM |
| Cairn Energy |
| G4S |
| Wednesday 16 May |
| Indivior |
| National Express Group |
| Mondi |
| Merchants Trust |
| Premier Oil |
| Chesnara |
| Jupiter Fund Management |
| Moss Bros |
| Coats Group |
| Ophir Energy |
| Cineworld Group |
| Tritax Big Box REIT |
| Secure Trust Bank |
| Charter Court Financial Services Group |
| Utilitywise |
| Fenner (re acquisition by Michelin) |
| Thursday 17 May |
| Just Group |
| Hill & Smith Holdings |
| Lidco Group |
| Fevertree Drinks |
| Highcroft Investments |
| esure Group |
| Foxtons Group |
| Hiscox |
| Prudential |
| Next |
| North Midland Construction |
| Legal & General Group |
| Vectura Group |
| Regional REIT |
| Staffline Group |
| Robert Walters |
| Genel Energy |
| TI Fluid Systems |
| Friday 18 May |
| Paddy Power Betfair |
| Independent News & Media |
| AstraZeneca |
| Computacenter |
| Clarke (T) |
| Petrofac |
| John Menzies |
| Derwent London |
| Hikma Pharmaceuticals |
| NEX Group (re acquisition by CME London) |
| Monday 21 May |
| BP |
| Cloudcall Group |
| Restore |
| 4D Pharma |
| TBC Bank Group |
| Secure Income REIT |
17 May 2022 11:07
IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial
4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed.
Read more